Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication

Tao Wang, Marshall Elam, William P. Forbes, Jianhua Zhong, Katsuyuki Nakajima

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Elevated triglyceride-rich lipoproteins and reduced high-density lipoproteins (HDL) are associated with the development of intermittent claudication (IC), a life-limiting symptom of peripheral arterial disease. Cilostazol, a potent platelet inhibitor and vasodilator, lowers triglycerides and increases HDL concentrations in addition to increasing walking distance in patients with intermittent claudication. However, the association of remnant lipoproteins (a more atherogenic subset of triglyceride-rich lipoproteins) and peripheral arterial disease and the effects of cilostazol on remnant lipoproteins have not been studied. Methods and results: We quantified plasma remnant lipoprotein concentrations using the remnant lipoprotein-cholesterol assay (RLP-C). Patients with intermittent claudication (n=415) had significantly higher remnant lipoprotein concentrations compared to reference subjects (n=874; 0.31±0.32 versus 0.24±0.17mmol/l, P<0.001) in addition to elevated total triglyceride (2.67±1.92 versus 1.92±1.24mmol/l, P<0.001) and reduced high-density lipoprotein (HDL) cholesterol concentrations (1.06±0.31 versus 1.22±0.36mmol/l, P<0.001). Cilostazol treatment (100mg, b.i.d.) in patients with intermittent claudication (n=56) for 6 months resulted in 20% reduction of remnant lipoprotein-cholesterol (from 0.27±0.21 to 0.22±0.09mmol/l, P<0.05) versus no significant change (from 0.26±0.17 to 0.27±0.12mmol/l) in the placebo group (n=67). Cilostazol also reduced triglyceride concentrations significantly (from 2.32±1.46 to 1.79±0.72mmol/l, P<0.01, in the cilostazol group versus 2.38±1.39 to 2.25±1.19mmol/l in the placebo group) and increased HDL cholesterol concentrations (from 1.06±0.23 to 1.24±0.34mmol/l, P<0.001) in the cilostazol group versus no significant change (1.06±0.34 to 1.09±0.36mmol/l) in the placebo group. Pentoxifylline (400mg, t.i.d.) did not have any significant effects on lipid variables (n=66). Conclusions: Remnant lipoprotein concentrations are significantly elevated in patients with intermittent claudication and can be reduced by cilostazol. Reduction of remnant lipoproteins may provide a long-term benefit to the patients with symptomatic peripheral arterial disease.

Original languageEnglish (US)
Pages (from-to)337-342
Number of pages6
JournalAtherosclerosis
Volume171
Issue number2
DOIs
StatePublished - Jan 1 2003

Fingerprint

Intermittent Claudication
Lipoproteins
Triglycerides
Peripheral Arterial Disease
Placebos
HDL Lipoproteins
HDL Cholesterol
Pentoxifylline
cilostazol
lipoprotein cholesterol
Platelet Aggregation Inhibitors
Vasodilator Agents
Walking
Lipids

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. / Wang, Tao; Elam, Marshall; Forbes, William P.; Zhong, Jianhua; Nakajima, Katsuyuki.

In: Atherosclerosis, Vol. 171, No. 2, 01.01.2003, p. 337-342.

Research output: Contribution to journalArticle

Wang, Tao ; Elam, Marshall ; Forbes, William P. ; Zhong, Jianhua ; Nakajima, Katsuyuki. / Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. In: Atherosclerosis. 2003 ; Vol. 171, No. 2. pp. 337-342.
@article{496d6439f6c64c92a18eb4fe08de2a3f,
title = "Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication",
abstract = "Background: Elevated triglyceride-rich lipoproteins and reduced high-density lipoproteins (HDL) are associated with the development of intermittent claudication (IC), a life-limiting symptom of peripheral arterial disease. Cilostazol, a potent platelet inhibitor and vasodilator, lowers triglycerides and increases HDL concentrations in addition to increasing walking distance in patients with intermittent claudication. However, the association of remnant lipoproteins (a more atherogenic subset of triglyceride-rich lipoproteins) and peripheral arterial disease and the effects of cilostazol on remnant lipoproteins have not been studied. Methods and results: We quantified plasma remnant lipoprotein concentrations using the remnant lipoprotein-cholesterol assay (RLP-C). Patients with intermittent claudication (n=415) had significantly higher remnant lipoprotein concentrations compared to reference subjects (n=874; 0.31±0.32 versus 0.24±0.17mmol/l, P<0.001) in addition to elevated total triglyceride (2.67±1.92 versus 1.92±1.24mmol/l, P<0.001) and reduced high-density lipoprotein (HDL) cholesterol concentrations (1.06±0.31 versus 1.22±0.36mmol/l, P<0.001). Cilostazol treatment (100mg, b.i.d.) in patients with intermittent claudication (n=56) for 6 months resulted in 20{\%} reduction of remnant lipoprotein-cholesterol (from 0.27±0.21 to 0.22±0.09mmol/l, P<0.05) versus no significant change (from 0.26±0.17 to 0.27±0.12mmol/l) in the placebo group (n=67). Cilostazol also reduced triglyceride concentrations significantly (from 2.32±1.46 to 1.79±0.72mmol/l, P<0.01, in the cilostazol group versus 2.38±1.39 to 2.25±1.19mmol/l in the placebo group) and increased HDL cholesterol concentrations (from 1.06±0.23 to 1.24±0.34mmol/l, P<0.001) in the cilostazol group versus no significant change (1.06±0.34 to 1.09±0.36mmol/l) in the placebo group. Pentoxifylline (400mg, t.i.d.) did not have any significant effects on lipid variables (n=66). Conclusions: Remnant lipoprotein concentrations are significantly elevated in patients with intermittent claudication and can be reduced by cilostazol. Reduction of remnant lipoproteins may provide a long-term benefit to the patients with symptomatic peripheral arterial disease.",
author = "Tao Wang and Marshall Elam and Forbes, {William P.} and Jianhua Zhong and Katsuyuki Nakajima",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/j.atherosclerosis.2003.08.017",
language = "English (US)",
volume = "171",
pages = "337--342",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication

AU - Wang, Tao

AU - Elam, Marshall

AU - Forbes, William P.

AU - Zhong, Jianhua

AU - Nakajima, Katsuyuki

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background: Elevated triglyceride-rich lipoproteins and reduced high-density lipoproteins (HDL) are associated with the development of intermittent claudication (IC), a life-limiting symptom of peripheral arterial disease. Cilostazol, a potent platelet inhibitor and vasodilator, lowers triglycerides and increases HDL concentrations in addition to increasing walking distance in patients with intermittent claudication. However, the association of remnant lipoproteins (a more atherogenic subset of triglyceride-rich lipoproteins) and peripheral arterial disease and the effects of cilostazol on remnant lipoproteins have not been studied. Methods and results: We quantified plasma remnant lipoprotein concentrations using the remnant lipoprotein-cholesterol assay (RLP-C). Patients with intermittent claudication (n=415) had significantly higher remnant lipoprotein concentrations compared to reference subjects (n=874; 0.31±0.32 versus 0.24±0.17mmol/l, P<0.001) in addition to elevated total triglyceride (2.67±1.92 versus 1.92±1.24mmol/l, P<0.001) and reduced high-density lipoprotein (HDL) cholesterol concentrations (1.06±0.31 versus 1.22±0.36mmol/l, P<0.001). Cilostazol treatment (100mg, b.i.d.) in patients with intermittent claudication (n=56) for 6 months resulted in 20% reduction of remnant lipoprotein-cholesterol (from 0.27±0.21 to 0.22±0.09mmol/l, P<0.05) versus no significant change (from 0.26±0.17 to 0.27±0.12mmol/l) in the placebo group (n=67). Cilostazol also reduced triglyceride concentrations significantly (from 2.32±1.46 to 1.79±0.72mmol/l, P<0.01, in the cilostazol group versus 2.38±1.39 to 2.25±1.19mmol/l in the placebo group) and increased HDL cholesterol concentrations (from 1.06±0.23 to 1.24±0.34mmol/l, P<0.001) in the cilostazol group versus no significant change (1.06±0.34 to 1.09±0.36mmol/l) in the placebo group. Pentoxifylline (400mg, t.i.d.) did not have any significant effects on lipid variables (n=66). Conclusions: Remnant lipoprotein concentrations are significantly elevated in patients with intermittent claudication and can be reduced by cilostazol. Reduction of remnant lipoproteins may provide a long-term benefit to the patients with symptomatic peripheral arterial disease.

AB - Background: Elevated triglyceride-rich lipoproteins and reduced high-density lipoproteins (HDL) are associated with the development of intermittent claudication (IC), a life-limiting symptom of peripheral arterial disease. Cilostazol, a potent platelet inhibitor and vasodilator, lowers triglycerides and increases HDL concentrations in addition to increasing walking distance in patients with intermittent claudication. However, the association of remnant lipoproteins (a more atherogenic subset of triglyceride-rich lipoproteins) and peripheral arterial disease and the effects of cilostazol on remnant lipoproteins have not been studied. Methods and results: We quantified plasma remnant lipoprotein concentrations using the remnant lipoprotein-cholesterol assay (RLP-C). Patients with intermittent claudication (n=415) had significantly higher remnant lipoprotein concentrations compared to reference subjects (n=874; 0.31±0.32 versus 0.24±0.17mmol/l, P<0.001) in addition to elevated total triglyceride (2.67±1.92 versus 1.92±1.24mmol/l, P<0.001) and reduced high-density lipoprotein (HDL) cholesterol concentrations (1.06±0.31 versus 1.22±0.36mmol/l, P<0.001). Cilostazol treatment (100mg, b.i.d.) in patients with intermittent claudication (n=56) for 6 months resulted in 20% reduction of remnant lipoprotein-cholesterol (from 0.27±0.21 to 0.22±0.09mmol/l, P<0.05) versus no significant change (from 0.26±0.17 to 0.27±0.12mmol/l) in the placebo group (n=67). Cilostazol also reduced triglyceride concentrations significantly (from 2.32±1.46 to 1.79±0.72mmol/l, P<0.01, in the cilostazol group versus 2.38±1.39 to 2.25±1.19mmol/l in the placebo group) and increased HDL cholesterol concentrations (from 1.06±0.23 to 1.24±0.34mmol/l, P<0.001) in the cilostazol group versus no significant change (1.06±0.34 to 1.09±0.36mmol/l) in the placebo group. Pentoxifylline (400mg, t.i.d.) did not have any significant effects on lipid variables (n=66). Conclusions: Remnant lipoprotein concentrations are significantly elevated in patients with intermittent claudication and can be reduced by cilostazol. Reduction of remnant lipoproteins may provide a long-term benefit to the patients with symptomatic peripheral arterial disease.

UR - http://www.scopus.com/inward/record.url?scp=0344741545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344741545&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2003.08.017

DO - 10.1016/j.atherosclerosis.2003.08.017

M3 - Article

VL - 171

SP - 337

EP - 342

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -